Wide Ranks

ACRS

Aclaris Therapeutics, Inc.

3.82

Top Statistics
Market Cap 272 M Forward PE -7.30 Revenue Growth -53.20 %
Current Ratio 7.03 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -136.65 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.37 Enterprise / Revenue 5.44 Price To Sales Trailing12 Months 10.08
Profitability
Profit Margins -136.65 % Operating Margins -222.53 %
Balance Sheet
Total Cash 127 M Total Cash Per Share 1.79 Total Debt 2 M
Total Debt To Equity 1.73 Current Ratio 7.03 Book Value Per Share 1.82
All Measures
Short Ratio 143.00 % Message Board Id finmb_216879819 Shares Short Prior Month 1 M
Return On Equity -0.2583 City Wayne Uuid 7ce3d940-7ceb-3e8d-9e47-4f01c59483ef
Previous Close 3.63 First Trade Date Epoch Utc 1 B Book Value 1.82
Beta 0.1160 Total Debt 2 M Volume 822411
Price To Book 2.10 Fifty Two Week Low 0.8000 Total Cash Per Share 1.79
Total Revenue 27 M Shares Short Previous Month Date 1 B Target Median Price 7.00
Max Age 86400 Recommendation Mean 2.00 Sand P52 Week Change 0.3133
Operating Margins -222.53 % Target Mean Price 7.60 Net Income To Common -37004000
Short Percent Of Float 0.0260 Implied Shares Outstanding 71 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 10 M Average Volume10days 10 M
Total Cash 127 M Next Fiscal Year End 1 B Revenue Per Share 0.3810
Held Percent Insiders 0.0359 Ebitda Margins -229.71 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 3.63
Target Low Price 3.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.93
Open 3.64 Free Cashflow -22053376 State PA
Dividend Yield 0.00 % Return On Assets -0.1939 Time Zone Short Name EST
Trailing Eps -0.5200 Day Low 3.64 Address1 701 Lee Road
Shares Outstanding 71 M Price Hint 4 Target High Price 13.00
Website https://www.aclaristx.com 52 Week Change 3.37 Average Volume 2 M
Forward Eps -0.5800 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 680.60 % Is_sp_500 False Regular Market Day High 3.94
Profit Margins -136.65 % Debt To Equity 1.73 Fifty Two Week High 5.17
Day High 3.94 Shares Short 1 M Regular Market Open 3.64
Industry Key diagnostics-research Earnings Growth 0.00 % Enterprise To Revenue 5.44
Revenue Growth -53.20 % Shares Percent Shares Out 0.0218 Operating Cashflow -17898000
Currency USD Time Zone Full Name America/New_York Market Cap 272 M
Is_nasdaq_100 False Zip 19087 Quote Type EQUITY
Industry Diagnostics & Research Long Name Aclaris Therapeutics, Inc. Regular Market Day Low 3.64
Held Percent Institutions 0.9028 Current Price 3.82 Address2 Suite 103
Enterprise To Ebitda -2.37 Financial Currency USD Current Ratio 7.03
Gross Margins -284.04 % Industry Disp Diagnostics & Research Number Of Analyst Opinions 5
Country United States Float Shares 55 M Two Hundred Day Average 1.39
Enterprise Value 147 M Price To Sales Trailing12 Months 10.08 Forward PE -7.30
Regular Market Volume 822411 Ebitda -62202000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.

The company operates through two segments, Therapeutics and Contract Research.

The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.

The Contract Research segment provides laboratory services.

It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases.

The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.